Revolutionizing Cancer Treatment: New Tests and Drugs at ASCO Breakthrough

Upcoming presentations at the ASCO meeting in Chicago highlight potential practice-changing studies in cancer care. Veracyte's Prosigna test may allow some high-risk breast cancer patients to avoid chemotherapy, while their Decipher test helps tailor prostate cancer treatment. A new oral drug for gastrointestinal cancers aids in maintaining necessary platelet levels for chemotherapy.

The upcoming American Society of Clinical Oncology (ASCO) meeting in Chicago promises to showcase groundbreaking studies with the potential to transform cancer care practices. Veracyte's Prosigna test could allow high-risk breast cancer patients to safely avoid chemotherapy, offering a significant shift in treatment protocols.

A randomized trial involving over 4,400 early-stage breast cancer patients revealed that two-thirds who used the Prosigna genomic test avoided chemo, achieving a five-year cancer-free survival rate comparable to those who received standard chemotherapy. This test examines 50 gene activities in tumor tissues to assess chemotherapy necessity, a breakthrough in reducing physical and emotional chemotherapy impacts.

Additionally, Veracyte's Decipher test identifies prostate cancer patients who might benefit from adding chemotherapy drug docetaxel to standard treatment. The ASCO meeting will also discuss an oral medication, Doptelet, proven effective in maintaining platelet counts for continued chemotherapy in gastrointestinal cancer patients, circumventing the need for injections.